The earnings call reflected a strong quarter for Boston Scientific, with significant growth across key segments such as Cardiovascular, Electrophysiology, and Asia Pacific regions. Noteworthy achievements in product launches and strategic acquisitions further bolstered the company's positive outlook. However, challenges such as the discontinuation of the ACURATE valve and tariff impacts were notable lowlights. Overall, the highlights significantly outweighed the lowlights.

Company Guidance

During the Boston Scientific Second Quarter 2025 Earnings Call, the company reported impressive financial metrics, with total company operational sales growing by 22% and organic sales by 17%, surpassing their guidance range of 13% to 15%. Adjusted earnings per share (EPS) reached $0.75, a 23% increase, exceeding the high-end guidance of $0.71 to $0.73. The adjusted operating margin was reported at 27.6%. Looking forward, Boston Scientific raised its full-year guidance for organic growth to 14% to 15% and anticipates a full-year adjusted EPS between $2.95 and $2.99, reflecting an 18% to 19% growth. Regional performance varied, with the U.S. growing 31% operationally, Europe, Middle East, and Africa (EMEA) at 2% operationally (7% excluding certain product discontinuations), and Asia Pacific growing 15% operationally. The company highlighted strong growth in specific business areas such as Urology, Endoscopy, Neuromodulation, and Cardiology, with the Cardiovascular segment notably leading the first half of 2025. Furthermore, the guidance for the third quarter of 2025 predicts an organic growth of 12% to 14% and an adjusted EPS of $0.70 to $0.72.

Outperformance in Q2 2025

Total company operational sales grew 22% and organic sales grew 17%, exceeding the guidance range of 13% to 15%.

Cardiovascular Segment Success

The U.S. market grew by 31%, driven by the cardiovascular portfolio, and Cardiology sales increased by 28%.

Strong Growth in Asia Pacific

Asia Pacific saw a 15% operational growth, with Japan and China contributing significant double-digit growth.

Impressive Performance in WATCHMAN and FARAPULSE

WATCHMAN grew by 28%, and Electrophysiology sales grew by 94%, driven by the FARAPULSE launch.

Endoscopy and Neuromodulation Strength

Endoscopy grew 8% globally, and Neuromodulation sales increased by 7% with strong performance in DBS.

Successful M&A Activity

Acquisitions of SoniVie and Intera Medical to expand offerings in Interventional Cardiology and Peripheral Interventions.

Adjusted EPS Surpasses Expectations

Adjusted EPS of $0.75 grew 23%, exceeding the high end of the guidance range.

Boston Scientific (BSX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BSX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 22, 2025	2025 (Q3)	0.71 / -	0.63	―	―	―
Jul 23, 2025	2025 (Q2)	0.72 / 0.75	0.62	20.97% (+0.13)
Apr 23, 2025	2025 (Q1)	0.67 / 0.75	0.56	33.93% (+0.19)
Feb 05, 2025	2024 (Q4)	0.66 / 0.70	0.55	27.27% (+0.15)
Oct 23, 2024	2024 (Q3)	0.59 / 0.63	0.5	26.00% (+0.13)
Jul 24, 2024	2024 (Q2)	0.58 / 0.62	0.53	16.98% (+0.09)
Apr 24, 2024	2024 (Q1)	0.51 / 0.56	0.47	19.15% (+0.09)
Jan 31, 2024	2023 (Q4)	0.51 / 0.55	0.45	22.22% (+0.10)
Oct 26, 2023	2023 (Q3)	0.48 / 0.50	0.43	16.28% (+0.07)
Jul 27, 2023	2023 (Q2)	0.49 / 0.53	0.44	20.45% (+0.09)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BSX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 23, 2025	$103.16	$107.76	+4.46%
Apr 23, 2025	$95.05	$98.92	+4.07%
Feb 05, 2025	$103.54	$104.97	+1.38%
Oct 23, 2024	$88.01	$87.45	-0.64%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.